These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17371824)

  • 21. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
    Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
    Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
    J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
    Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.
    Howe AY; Bloom J; Baldick CJ; Benetatos CA; Cheng H; Christensen JS; Chunduru SK; Coburn GA; Feld B; Gopalsamy A; Gorczyca WP; Herrmann S; Johann S; Jiang X; Kimberland ML; Krisnamurthy G; Olson M; Orlowski M; Swanberg S; Thompson I; Thorn M; Del Vecchio A; Young DC; van Zeijl M; Ellingboe JW; Upeslacis J; Collett M; Mansour TS; O'Connell JF
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4813-21. PubMed ID: 15561861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
    PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
    Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
    Eltahla AA; Tay E; Douglas MW; White PA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
    Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1).
    Miyamoto M; Kato T; Date T; Mizokami M; Wakita T
    Intervirology; 2006; 49(1-2):37-43. PubMed ID: 16166787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.
    Robida JM; Nelson HB; Liu Z; Tang H
    J Virol; 2007 Jun; 81(11):5829-40. PubMed ID: 17376913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
    Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
    Howe AY; Cheng H; Thompson I; Chunduru SK; Herrmann S; O'Connell J; Agarwal A; Chopra R; Del Vecchio AM
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4103-13. PubMed ID: 16940072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.